Last reviewed · How we verify
GEMOX chemotherapy
GEMOX chemotherapy combines gemcitabine and oxaliplatin to target rapidly dividing cancer cells.
GEMOX chemotherapy combines gemcitabine and oxaliplatin to target rapidly dividing cancer cells. Used for Advanced pancreatic cancer, Advanced ovarian cancer.
At a glance
| Generic name | GEMOX chemotherapy |
|---|---|
| Also known as | Gemcitabine, Oxaliplatin |
| Sponsor | Prof. Massimo Aglietta |
| Drug class | chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while oxaliplatin is a platinum-based drug that cross-links DNA, causing cell death. This combination therapy aims to enhance the efficacy of each individual drug by targeting cancer cells from multiple angles.
Approved indications
- Advanced pancreatic cancer
- Advanced ovarian cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Fatigue
Key clinical trials
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
- Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (PHASE3)
- Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
- Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer (PHASE1, PHASE2)
- Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (PHASE1, PHASE2)
- A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) (PHASE3)
- A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China (PHASE3)
- PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |